<img src="https://ce.sleepchicks.com/wp-content/plugins/elementor/assets/images/placeholder.png" title="" alt="" loading="lazy" />
<img width="1024" height="272" src="https://ce.sleepchicks.com/wp-content/uploads/2024/12/SBMedia-billboards-1024x272.png" alt="" srcset="https://i0.wp.com/ce.sleepchicks.com/wp-content/uploads/2024/12/SBMedia-billboards.png?resize=1024%2C272&ssl=1 1024w, https://i0.wp.com/ce.sleepchicks.com/wp-content/uploads/2024/12/SBMedia-billboards.png?resize=300%2C80&ssl=1 300w, https://i0.wp.com/ce.sleepchicks.com/wp-content/uploads/2024/12/SBMedia-billboards.png?resize=768%2C204&ssl=1 768w, https://i0.wp.com/ce.sleepchicks.com/wp-content/uploads/2024/12/SBMedia-billboards.png?resize=1536%2C408&ssl=1 1536w, https://i0.wp.com/ce.sleepchicks.com/wp-content/uploads/2024/12/SBMedia-billboards.png?resize=2048%2C543&ssl=1 2048w, https://i0.wp.com/ce.sleepchicks.com/wp-content/uploads/2024/12/SBMedia-billboards.png?w=3000&ssl=1 3000w" sizes="(max-width: 1024px) 100vw, 1024px" />
Deleted: Added: <h4>
Table of Contents </h4>
<svg aria-hidden="true" viewBox="0 0 448 512" xmlns="http://www.w3.org/2000/svg"><path d="M207.029 381.476L12.686 187.132c-9.373-9.373-9.373-24.569 0-33.941l22.667-22.667c9.357-9.357 24.522-9.375 33.901-.04L224 284.505l154.745-154.021c9.379-9.335 24.544-9.317 33.901.04l22.667 22.667c9.373 9.373 9.373 24.569 0 33.941L240.971 381.476c-9.373 9.372-24.569 9.372-33.942 0z"></path></svg>
<svg aria-hidden="true" viewBox="0 0 448 512" xmlns="http://www.w3.org/2000/svg"><path d="M240.971 130.524l194.343 194.343c9.373 9.373 9.373 24.569 0 33.941l-22.667 22.667c-9.357 9.357-24.522 9.375-33.901.04L224 227.495 69.255 381.516c-9.379 9.335-24.544 9.317-33.901-.04l-22.667-22.667c-9.373-9.373-9.373-24.569 0-33.941L207.03 130.525c9.372-9.373 24.568-9.373 33.941-.001z"></path></svg>
Added: <svg aria-hidden="true" viewBox="0 0 1000 1000" xmlns="http://www.w3.org/2000/svg"><path d="M500 975V858C696 858 858 696 858 500S696 142 500 142 142 304 142 500H25C25 237 238 25 500 25S975 237 975 500 763 975 500 975Z"></path></svg>
<h1>Daridorexant for Insomnia During the Menopausal Transition:
</h1>
<h1>Subgroup Findings Suggest Clinical Benefit</h1>
<p>Insomnia affects a large proportion of women during the menopausal transition, yet targeted treatments remain limited. A new subgroup analysis from a Phase 3 trial (NCT03545191) sheds light on the efficacy of daridorexant, a dual orexin receptor antagonist (DORA), in peri-menopausal women aged 47–55 with insomnia disorder [1].</p>
<h2>🧪 Study Design & Population</h2>
<p>This was a post-hoc subgroup analysis of a larger randomized, placebo-controlled trial evaluating daridorexant 25 mg and 50 mg once nightly.</p><p>The subgroup included 117 women aged 47–55:</p><p>50 mg group (n = 35)</p><p>25 mg group (n = 43)</p><p>Placebo (n = 39)</p>
<h2>🛏️ Efficacy Outcomes</h2>
<p>Sleep Maintenance (WASO):</p><p>At Month 1:</p><p>Daridorexant 50 mg: –42.4 min (95% CI –52.5 to –32.3)</p><p>Placebo: –12.7 min (95% CI –22.4 to –3.0)</p><p>At Month 3:</p><p>50 mg: –42.9 min vs Placebo: –29.1 min</p><p>Latency to Persistent Sleep (LPS):</p><p>At Month 3:</p><p>50 mg: –18.7 min (95% CI –28.8 to –8.6)</p><p>Placebo: –13.0 min (95% CI –22.5 to –3.6)</p><p>Self-Reported Total Sleep Time (sTST):</p><p>50 mg showed numerically greater improvement at Month 3 (66.4 min vs 51.1 min for placebo)</p><p>Daytime Functioning (IDSIQ score):</p><p>50 mg group:</p><p>Month 1: –14.7</p><p>Month 3: –21.9</p><p>Placebo:</p><p>Month 1: –3.6</p><p>Month 3: –10.3</p>
<h2>⚠️ Safety and Tolerability</h2>
<p>TEAEs were reported in:</p><p>50 mg: 46%</p><p>25 mg: 35%</p><p>Placebo: 38%</p><p>Most common: nasopharyngitis, headache, gastroenteritis</p><p>No serious AEs in daridorexant groups; only placebo had discontinuations due to AEs in this subgroup</p>
<h2>💬 Clinical Relevance</h2>
<p>The findings support the utility of daridorexant 50 mg in peri-menopausal women, improving both objective and subjective sleep metrics and daytime functioning.</p><p>Given that this subgroup faces unique physiological and psychological sleep disruptors, a tailored pharmacologic option may be of particular value.</p><p>The safety profile remained favorable, with low rates of somnolence or next-day sedation.</p>
<h2>⚠️ Caveats</h2>
<p>Post-hoc nature of the analysis limits inferential power</p><p>Sample size is relatively small (n = 117 total)</p><p>Long-term effects in this specific population remain unknown</p>
<h2>🧭 Conclusion</h2>
<p>Daridorexant shows promise for treating insomnia in women navigating the menopausal transition, particularly at the 50 mg dose. While these findings are exploratory, they highlight the need for more sex-specific and hormone-phase–sensitive approaches to sleep medicine.</p><p>References:</p><p>Meglio M. Daridorexant Provides Relief for Insomnia in Women During Menopausal Transition. NeurologyLive, Sept 2025.</p><p>Schaedel Z, et al. Phase 3 Analysis of Daridorexant in Perimenopausal Insomnia. Presented at World Sleep 2025.</p><p>Idorsia Pharmaceuticals. Daridorexant Mechanism of Action and Clinical Data Summary.</p>